It is the twentieth anniversary of the new patent act in January 2025. The post-patent (P20) era is a story of resilience, determination, and charting a course that set global ambitions, a story of finding opportunity in adversity. It is a story for case studies in business schools, in international studies, in global health efforts.

Tariffs and Indian Generics: Is Trump Cutting His Nose to Spite His Face?

Trump’s Tariffs Threaten US Drug Affordability The Value of...

7 Ways to Increase Productivity of Pharma Sales Reps

With access to HCPs becoming a daunting task for...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

What ChrysCapital’s Takeover Of Novartis India Really Means

When ChrysCapital, one of India's oldest and largest homegrown...

Biological E. Limited appointments Manishkumar Munot as Chief Business Officer—Vaccines.

Manishkumar Munot has joined Biological E. Limited as Chief...

Big Pharma and the Obesity War – Science to Subpoenas

Two pharmaceutical giants are currently locked in a high-stakes...

Lifetime Value of a Patient: Why Indian Pharma must Transition from Product-centric Selling to Patient-centric Healthcare

Introduction For decades, the Indian pharmaceutical industry has measured success...

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

Marketing

What ChrysCapital’s Takeover Of Novartis India Really Means

When ChrysCapital, one of India's oldest and largest homegrown...

Biological E. Limited appointments Manishkumar Munot as Chief Business Officer—Vaccines.

Manishkumar Munot has joined Biological E. Limited as Chief...

Big Pharma and the Obesity War – Science to Subpoenas

Two pharmaceutical giants are currently locked in a high-stakes...

Lifetime Value of a Patient: Why Indian Pharma must Transition from Product-centric Selling to Patient-centric Healthcare

Introduction For decades, the Indian pharmaceutical industry has measured success...

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

Policies/Sales

What ChrysCapital’s Takeover Of Novartis India Really Means

When ChrysCapital, one of India's oldest and largest homegrown...

Biological E. Limited appointments Manishkumar Munot as Chief Business Officer—Vaccines.

Manishkumar Munot has joined Biological E. Limited as Chief...

Big Pharma and the Obesity War – Science to Subpoenas

Two pharmaceutical giants are currently locked in a high-stakes...

Lifetime Value of a Patient: Why Indian Pharma must Transition from Product-centric Selling to Patient-centric Healthcare

Introduction For decades, the Indian pharmaceutical industry has measured success...

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

Strategy

What ChrysCapital’s Takeover Of Novartis India Really Means

When ChrysCapital, one of India's oldest and largest homegrown...

Biological E. Limited appointments Manishkumar Munot as Chief Business Officer—Vaccines.

Manishkumar Munot has joined Biological E. Limited as Chief...

Big Pharma and the Obesity War – Science to Subpoenas

Two pharmaceutical giants are currently locked in a high-stakes...

Lifetime Value of a Patient: Why Indian Pharma must Transition from Product-centric Selling to Patient-centric Healthcare

Introduction For decades, the Indian pharmaceutical industry has measured success...

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Indian Pharma – The Emerging Role of Hybrid Sales Model

COVID-19 has accelerated the shift in how pharma was engaging with HCPs, professional organisations and even patients in India from a sales to more of a scientific, unbiased and balanced marketing communications. As one of the business leader from a prominent MNC said, “For the first time we are seeing a certain shift in HCP’s preference for scientific communication for innovators companies. MSLs and scientific operation teams will be playing a key role in the near future.”